Results 241 to 250 of about 70,621 (279)

Pertuzumab/trastuzumab/trastuzumab-emtansine

Reactions Weekly, 2020
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2022
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2023
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2020
  +4 more sources

Trastuzumab

Reactions Weekly, 2021
openaire   +2 more sources

Trastuzumab/trastuzumab emtansine

Reactions Weekly, 2017
openaire   +1 more source

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

New England Journal of Medicine, 2020
Kohei Shitara, Yung-Jue Bang, Daisuke Sakai   +2 more
exaly  

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Lancet, The, 2023
exaly  

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

New England Journal of Medicine, 2022
Shanu Modi, Joohyuk Sohn, Maria Vidal
exaly  

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

New England Journal of Medicine, 2020
Shanu Modi, Cristina Saura, Yeon Hee Park   +2 more
exaly